Amgen is a large biotechnology company that develops and sells medicines. Its filings show it lobbied Congress on health and pharmaceutical issues, including drug pricing and a bill called the Biosimilar Red Tape Elimination Act (H.R. 5526). The reports list $20,000 spent and that Amgen used a lobby firm, Sightline Advocacy.
Show the dominant industry call, how mixed the client looks, and the allocation across the top labeled sectors.
Annual totals based on disclosed filing amounts.
Issue rankings are based on disclosed activity mentions, with filing amounts apportioned evenly across issues within the same filing.
The lobbying registrants handling this client, ranked by disclosed filing amounts.
Lobbyists are ranked by appearances and an equal share of each filing's reported amount.
TYLER STEPHENS
The latest disclosures for this client.
SIGHTLINE ADVOCACY, LLC
Q2SIGHTLINE ADVOCACY, LLC
Q1The entities named in disclosed activities are the clearest available signal for where the client is aiming attention.
SIGHTLINE ADVOCACY, LLC
SARAH MOXLEY
SIGHTLINE ADVOCACY, LLC
SIGHTLINE ADVOCACY, LLC
Q4SIGHTLINE ADVOCACY, LLC
RR